CLINICAL AND PATHOGENETIC EFFECTIVENESS OF VARIOUS PHARMACOTHERAPEUTIC MODES IN SEVERE BRONCHIAL ASTHMA IN CHILDREN

Open prospective randomized study in parallel groups was carried out to evaluate clinical (the amount of children who reached the control level by goal) and pathogenetic (the influence on the dynamics of the antiapoptotic eosinophil effectors expression) effectiveness of various pharma cotherapeutic...

Full description

Saved in:
Bibliographic Details
Main Authors: L.M. Ogorodova, I.A. Deev, I.I. Ivanchuk
Format: Article
Language:Russian
Published: Union of pediatricians of Russia 2006-06-01
Series:Педиатрическая фармакология
Online Access:https://www.pedpharma.ru/jour/article/view/561
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839587232742113280
author L.M. Ogorodova
I.A. Deev
I.I. Ivanchuk
author_facet L.M. Ogorodova
I.A. Deev
I.I. Ivanchuk
author_sort L.M. Ogorodova
collection DOAJ
description Open prospective randomized study in parallel groups was carried out to evaluate clinical (the amount of children who reached the control level by goal) and pathogenetic (the influence on the dynamics of the antiapoptotic eosinophil effectors expression) effectiveness of various pharma cotherapeutic modes in severe children's asthma. All patients (n = 60) underwent the evaluation of the expression of mRNA IL 5, bcl 2, bcl Xl against the backgrounds of the application of three modes of therapy (monotherapy by fluticasone propionate, combination of fluticasone propionate with sustained release theophyllines and fluticasone propionate with salmeterol). It has been found that usage of pharmacotherapeutic mode of fluticasone propionate with salmeterol by the end of the first month of treatment brings about the increase in the apoptotic activity of eosinophils, and by the end of the treatment period (24 weeks) — this criterion didn't differ from the control values. The usage of the combination of fluticasone propionate and salmeterol is the optimal pharmacotherapeutic mode for the treatment of severe asthmain children, as it ensures the achievement of the control over symptoms and is the most effective in the aspect of eosinophil apoptosis regulation, therefore results in slackening of inflammatory activity of the respiratory tract.Key words: severe bronchial asthma, children, eosinophils, apoptosis, IL 5, bcl 2, bcl-Xl, fluticasone propionate, salmeterol, sustaine-release theophyllines, treatment.
format Article
id doaj-art-b4961b78a8104ad5a89498b64d8cb91d
institution Matheson Library
issn 1727-5776
2500-3089
language Russian
publishDate 2006-06-01
publisher Union of pediatricians of Russia
record_format Article
series Педиатрическая фармакология
spelling doaj-art-b4961b78a8104ad5a89498b64d8cb91d2025-08-03T19:21:18ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892006-06-01332631557CLINICAL AND PATHOGENETIC EFFECTIVENESS OF VARIOUS PHARMACOTHERAPEUTIC MODES IN SEVERE BRONCHIAL ASTHMA IN CHILDRENL.M. Ogorodova0I.A. Deev1I.I. Ivanchuk2Siberian State Medical University, TomskSiberian State Medical University, TomskSiberian State Medical University, TomskOpen prospective randomized study in parallel groups was carried out to evaluate clinical (the amount of children who reached the control level by goal) and pathogenetic (the influence on the dynamics of the antiapoptotic eosinophil effectors expression) effectiveness of various pharma cotherapeutic modes in severe children's asthma. All patients (n = 60) underwent the evaluation of the expression of mRNA IL 5, bcl 2, bcl Xl against the backgrounds of the application of three modes of therapy (monotherapy by fluticasone propionate, combination of fluticasone propionate with sustained release theophyllines and fluticasone propionate with salmeterol). It has been found that usage of pharmacotherapeutic mode of fluticasone propionate with salmeterol by the end of the first month of treatment brings about the increase in the apoptotic activity of eosinophils, and by the end of the treatment period (24 weeks) — this criterion didn't differ from the control values. The usage of the combination of fluticasone propionate and salmeterol is the optimal pharmacotherapeutic mode for the treatment of severe asthmain children, as it ensures the achievement of the control over symptoms and is the most effective in the aspect of eosinophil apoptosis regulation, therefore results in slackening of inflammatory activity of the respiratory tract.Key words: severe bronchial asthma, children, eosinophils, apoptosis, IL 5, bcl 2, bcl-Xl, fluticasone propionate, salmeterol, sustaine-release theophyllines, treatment.https://www.pedpharma.ru/jour/article/view/561
spellingShingle L.M. Ogorodova
I.A. Deev
I.I. Ivanchuk
CLINICAL AND PATHOGENETIC EFFECTIVENESS OF VARIOUS PHARMACOTHERAPEUTIC MODES IN SEVERE BRONCHIAL ASTHMA IN CHILDREN
Педиатрическая фармакология
title CLINICAL AND PATHOGENETIC EFFECTIVENESS OF VARIOUS PHARMACOTHERAPEUTIC MODES IN SEVERE BRONCHIAL ASTHMA IN CHILDREN
title_full CLINICAL AND PATHOGENETIC EFFECTIVENESS OF VARIOUS PHARMACOTHERAPEUTIC MODES IN SEVERE BRONCHIAL ASTHMA IN CHILDREN
title_fullStr CLINICAL AND PATHOGENETIC EFFECTIVENESS OF VARIOUS PHARMACOTHERAPEUTIC MODES IN SEVERE BRONCHIAL ASTHMA IN CHILDREN
title_full_unstemmed CLINICAL AND PATHOGENETIC EFFECTIVENESS OF VARIOUS PHARMACOTHERAPEUTIC MODES IN SEVERE BRONCHIAL ASTHMA IN CHILDREN
title_short CLINICAL AND PATHOGENETIC EFFECTIVENESS OF VARIOUS PHARMACOTHERAPEUTIC MODES IN SEVERE BRONCHIAL ASTHMA IN CHILDREN
title_sort clinical and pathogenetic effectiveness of various pharmacotherapeutic modes in severe bronchial asthma in children
url https://www.pedpharma.ru/jour/article/view/561
work_keys_str_mv AT lmogorodova clinicalandpathogeneticeffectivenessofvariouspharmacotherapeuticmodesinseverebronchialasthmainchildren
AT iadeev clinicalandpathogeneticeffectivenessofvariouspharmacotherapeuticmodesinseverebronchialasthmainchildren
AT iiivanchuk clinicalandpathogeneticeffectivenessofvariouspharmacotherapeuticmodesinseverebronchialasthmainchildren